EDGE
  • home.svg
    Home
  • news.svg
    All updates
  • news.svg
    EDGE Insights
  • list.svg
    Industries
  • db-search.svg
    Company Search
  • company-list.svg
    My Watchlists (Beta)

Capricor Therapeutics

Overview
News
Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases. Its CAP-1002 is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. The company was founded in 2005 and is headquartered in Los Angeles, California.
HQ location:
Los Angeles, CA
Founded year:
2005
Employees:
11-50
IPO status:
Public
Total funding:
USD 179.5 mn
Last Funding:
USD 75.0 mn (Post IPO Equity; Oct 2024)
Last valuation:
-
Funding data are powered by Crunchbase
About EDGE
Contact Us
Resources
EDGE

Technology Research Made Effortless

Get a demo
Terms & conditionsPrivacy policyDo not sell my personal information
SPEEDA Edge is owned by Uzabase, the business intelligence and media company. ©2024 Uzabase, Inc. and Uzabase USA, Inc. All rights reserved.
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.